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ABSTRACT
Background and objectives: Promoted globally as an
evidence-based intervention in the prevention of HIV and
treatment of heroin addiction among people who inject
drugs (PWID), opioid substitution treatment (OST) can
help control emerging HIV epidemics among PWID. With
implementation in December 2014, Kenya is the third Sub-
Saharan African country to have introduced OST. We
combine dynamic mathematical modelling with qualitative
sociological research to examine the ‘promise of
methadone’ to Kenya.
Methods, setting and participants:We model the HIV
prevention impact of OST in Nairobi, Kenya, at different
levels of intervention coverage. We draw on thematic
analyses of 109 qualitative interviews with PWID, and 43
with stakeholders, to chart their narratives of expectation in
relation to the promise of methadone.
Results: The modelled impact of OST shows relatively
slight reductions in HIV incidence (5–10%) and prevalence
(2–4%) over 5 years at coverage levels (around 10%)
anticipated in the planned roll-out of OST. However, there
is a higher impact with increased coverage, with 40%
coverage producing a 20% reduction in HIV incidence,
even when accounting for relatively high sexual
transmissions. Qualitative findings emphasise a culture of
‘rationed expectation’ in relation to access to care and a
‘poverty of drug treatment opportunity’. In this context, the
promise of methadone may be narrated as a symbol of
hope—both for individuals and community—in relation to
addiction recovery.
Conclusions:Methadone offers HIV prevention potential,
but there is a need to better model the effects of sexual
HIV transmission in mediating the impact of OST among
PWID in settings characterised by a combination of
generalised and concentrated epidemics. We find that
individual and community narratives of methadone as
hope for recovery coexist with policy narratives positioning
methadone primarily in relation to HIV prevention. Our
analyses show the value of mixed methods approaches to
investigating newly-introduced interventions.
INTRODUCTION
Methadone is promoted globally as an ‘essen-
tial medicine’ as part of ‘evidence-based’
interventions for treating heroin addiction
and preventing HIV.1 Kenya is witnessing a
growing contribution to national HIV inci-
dence linked to drug injecting, with estimates
of HIV prevalence among people who inject
drugs (PWID) as high as 50% in Nairobi and
20% in the Coastal Province.2 3 Treatment for
heroin addiction in Kenya largely comprises
private-only short-term residential detoxiﬁca-
tion and rehabilitation, affordable to a few
and characterised by high relapse.4 With
Strengths and limitations of this study
▪ Using mathematical modelling, we estimate—for
the first time in an African setting and in the
context of a generalised HIV epidemic—the poten-
tial HIV prevention impacts of OST among people
who inject drugs.
▪ Using qualitative research, we describe narratives of
‘expectation’ linked to the promise of newly intro-
duced methadone treatment in a low-income setting.
▪ Our modelling shows reductions in HIV incidence
and prevalence among people who inject drugs
linked to the implementation of OST, especially at
higher coverage levels. However, we note that a rela-
tively high level of sexual transmissions in general-
ised epidemic settings may moderate these effects.
▪ Our qualitative research shows evidence of differ-
ent, and conflicting, framings of expectation in
relation to the promise of methadone, especially
between methadone as a hope for addiction recov-
ery and as a means of HIV prevention. The mean-
ings of methadone and of new intervention
technologies are negotiated locally, in context, and
extend beyond the global ‘evidence-base’.
▪ We acknowledge uncertainty in how our model
assesses sexual HIV transmission potential and thus
also the impact projections of OST. Future models
need to develop more reliable indicators of sexual
transmission among people who inject drugs.
▪ Qualitative data are inevitably shaped by the con-
texts in which they are produced and by the set-
tings of study, which may limit the generalisability
of these findings to other settings.
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international support, and following a cascade of policy
development, the Kenyan Government has endorsed the
incorporation of combination ‘harm reduction’ interven-
tions.5 Needle and syringe programmes (NSP) were intro-
duced in 2013. After 2 years of planning, methadone
substitution treatment was introduced in December 2014
as a primary element of HIV prevention and drug treat-
ment strategy. Kenya is the third Sub-Saharan African
country to introduce opioid substitution treatments
(OST).6 7 The incorporation of harm reduction, and the
introduction of OST, constitutes a major departure in
Kenyan drug policy, with potentially lasting effects in the
management of heroin addiction and linked health
harms. Just what is the ‘promise’ of methadone for
Kenya? What are the hopes and expectations that sur-
round its introduction? Combining qualitative data with
mathematical modelling, we consider the ‘promise of
methadone’ to Kenya. In so doing, we illustrate the value
of mixed-method approaches to implementation science
and to evidencing the social effects of intervention
potential.
The evidence-based promise of methadone
The HIV prevention effects of methadone in OST are
well founded.8 9 The odds of HIV seroconversion are
greater for those untreated or for those with interrupted
OST compared to those in continuous treatment.10
Methadone treatment is linked with reductions (as high
as 60%) in the prevalence and incidence of drug inject-
ing, and in syringe sharing (as high as 80%), as well as
reductions in overdose and acquisitive crime.8–11
Meta-analyses of studies conducted in high-income
countries associate methadone with a 54% reduction in
HIV among PWID.11
The impact of methadone in HIV prevention is
enhanced when delivered in combination with other
harm reduction interventions, such as NSP.9 12 In mid
(20–40%) to high (>40%) HIV prevalence epidemics
among PWID, a consistently high coverage of NSP can
be required to reduce HIV incidence.9 13 Yet introdu-
cing methadone at a coverage equivalent to that in
Western Europe (around 40% of PWID) can halve the
NSP coverage required to signiﬁcantly reduce new HIV
transmissions.14 For instance, in high (>40%) HIV preva-
lence settings in Russia, such as Saint Petersburg, where
there is low NSP coverage and no OST, introducing OST
to coverage levels equivalent to that in Western Europe
could reduce HIV incidence by 50% in 5 years.14 This is
an epidemiological scenario not dissimilar to Nairobi,
Kenya. Initial attempts to model the effects of OST in
Kenya have been based on crude data parameters and
used simple static models.15 These suggest that the intro-
duction of OST in combination with NSP at a very high
coverage of each (80% of PWID) would reduce incident
HIV infections of the order of 14% over 5 years.
The HIV prevention effects of methadone are
enhanced further through its combination with antiretro-
viral HIV treatment (ART).9 16 Methadone treatment
improves ART access,17 18 adherence16 19 20 and clinical
outcomes for people living with HIV who are opioid
dependent.18 21 ART retention and suppressed viral repli-
cation are higher among those in OST than among those
whose drug use is untreated, and higher among those in
OSTwho no longer inject compared to those in OSTwho
continue to inject.18 20 Conversely, interrupted OST
among people living with HIV may increase HIV-related
morbidity and mortality.21 22 Programmes integrating dir-
ectly administered ART with OST show good clinical out-
comes.23 Methadone treatment is also associated with
improved access and adherence to treatments for tuber-
culosis and hepatitis C.6 24
The social science of intervention expectation
There is a lack of critical mass of social scientiﬁc study
on the implementation processes of translating OST and
other harm reduction technologies into new contexts.
Qualitative research emphasises how social and environ-
mental factors—from national policies to programme
practices and community responses—shape how OST is
enacted.25 In describing the social relations of addiction
and drug treatment opportunity, this work informs more
effective models of treatment in terms of their feasibility,
accessibility and acceptability.26 This is especially import-
ant in lower income settings that bear a disproportionate
burden of HIV infections. There are also critically
inspired sociological studies exploring the ‘disciplinary
effects’ of OST in acting as ‘political’ instruments of nor-
mative conduct.27–29
The promise of new intervention has social effects. If
presented as having transformative potential, biomedical
interventions can generate hope as well as ratchet
upward patient and community expectations.30 The
public communication of technological innovations in
medical science in particular feeds a rhetoric of hope
linked to claims of scientiﬁc breakthrough of great
promise.31 Globalising accounts of promise linked to
HIV treatment provide recent examples.32 33 This not
only cautions against generating a rhetoric of aspiration
when promoting evidence-based interventions into new
settings and when projecting their potential impacts,33
but also it indicates that ‘evidence-based promise’ is
made locally in context, not only shaping future expect-
ation but also impacting on the present.30 33
In contrast to biomedical approaches evidencing inter-
vention promise, sociological approaches investigate inter-
vention expectations as products of social interaction among
actor networks in particular social contexts.34 In the case of
methadone, an ‘actor network’ may include: medical,
policy and criminal justice institutions; community, reli-
gious and media organisations; research and policy stake-
holders; health service and drug treatment providers;
people who use drugs and their signiﬁcant others; and
local affected communities and non-governmental organi-
sations. What is in negotiation in the translation of tech-
nologies of promise extends beyond the material
substance of the intervention (for instance, methadone)
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and its observed biomedical effects (for instance, reduced
injecting) to include multiple social meanings and effects.
The ‘object’ of methadone is therefore not as ‘ﬁxed’
as biomedical evidence implies, for it is open to inter-
pretation and re-interpretations, made locally. This is
powerfully demonstrated by the variable constructions of
‘methadone’ in context and time: for example, by
Russia’s resistance to OST in which methadone was con-
structed as a ‘toxic drug’ and ‘failed intervention’ of the
West;14 by the recent re-fashioning of methadone as a
medicine for addiction ‘recovery’ in ‘post-AIDS’ drug
policies of the UK and US which now de-emphasise
‘harm reduction’;35 36 and by the questioning of metha-
done as a treatment for opioid dependence in its early
days of introduction.37 In all such cases, expectation dis-
courses colour methadone experiences,26 with intervention
‘expectation’ being a product of its context rather than
of ‘evidence’ universally accepted and applied.
Methadone in Sub-Saharan Africa
Evidence of the effects of implementing methadone in
low-income settings is accumulating.6 38 The case of
Kenya offers a unique opportunity to systematically study
the impacts of combination harm reduction linked to
concentrated HIV epidemics in a generalised epidemic
context. Emerging evidence from neighbouring
Tanzania, one of only two settings in Sub-Saharan Africa
to implement methadone aside from Kenya, demon-
strates evidence of feasibility, with high levels of uptake as
well as retention, albeit with some evidence of gender
inequality.38 There is a dearth of published evidence of
the observed or projected HIV prevention impacts of
OST in the East African region, and an absence of imple-
mentation science investigating the social processes of
treatment engagement.
In Kenya, national policies are reorienting towards the
incorporation of harm reduction as HIV prevention,
including through the endorsement of NSP, and following
legal and policy change, the promise of methadone.5 NSP
delivered through community service organisations is esti-
mated to reach between 10% and 20% of PWID in
Nairobi, assuming estimates between 5031 and 10 937
PWID (and perhaps 18 000 nationally).39 Drug treatment
largely comprises private residential rehabilitation (here-
after ‘rehab’) offering detoxiﬁcation. In the absence of
state funding, this is prohibitively expensive to most, and
surveys (including our own) estimate drug treatment uptake
at around 10% of PWID (A Kurth, Personal communication,
August 2014). Under the coordination of the National AIDS
and STI Control Programme (NASCOP) and Ministry of
Health, and with international funding support, methadone
treatment is being implemented via speciﬁcally tailored
clinics in four sites (Malindi and Mombasa in Mombasa
County; Nairobi; and Kaliﬁ). Approximately 1500 patients
are envisaged in the ﬁrst year, approximately 800 in Nairobi,
with potential patients recruited, assessed and referred to
clinics via local community outreach projects also involved in
delivering NSP.
METHODS
We adopt an interdisciplinary mixed-method approach
combining mathematical modelling with qualitative data
analyses to explore the expectations of the effects of
implementing methadone in Kenya as well as to project
its potential HIV transmission impact.
Modelling
To estimate the HIV prevention impact of OST in
Kenya, we developed a mathematical model and sexual
HIV transmission among PWID. The model schematic is
shown in ﬁgure 1, whereas a detailed description of the
modelling and a full list of parameter values are
included in the online supplementary material. The
model assumes that PWID can either be infected by
other PWID due to sexual or injection-related HIV trans-
mission, or by non-PWID due to sexual-related HIV
transmission. Although little data exist in Kenya, PWID
are stratiﬁed into those with low-injection and high-
injection risk based on data from PWID in Tanzania,
although this is varied in the sensitivity analysis.40 A
proportion of sexual contacts are with non-PWID
(94.6%, A Kurth, Personal communication), which are
represented simply by a time-varying prevalence of
HIV and coverage of ART (see online supplementary
ﬁgure S1). HIV infection is modelled in a similar way
to other models with different stages of infection to
allow the model to incorporate important differences
in infectivity early and late in infection41 and while
on ART.42
The model incorporates the likely degree to which
HIV transmission among PWID is sexually driven. The
current yearly sexual HIV incidence among PWID is
estimated by calibrating a constant force of infection
model to the possible HIV prevalence achieved among
newly initiated PWID before they start injecting. Owing
to evidence suggesting that sexual risk behaviour is a
strong predictor of PWID HIV prevalence in
Tanzania,40 a high HIV prevalence among new PWID
in 2012 was assumed—double the 4% HIV prevalence
observed among individuals of similar age (25–
29 years) in Nairobi at that time.2 Different levels of
sexual HIV transmission are considered in the sensitiv-
ity analysis. The injecting HIV transmission probability
is calibrated to give a 20% HIV prevalence among
PWID in 2014, as found in recent respondent-driven
sampling (RDS) surveys in Nairobi (A Kurth, Personal
communication).
Data suggest that HIV prevalence in Kenya was
higher in the past than it is now, and so the model
assumes that new initiates to injecting and non-PWID
sexual partners had a higher HIV prevalence in the
past (see online supplementary ﬁgure S1).2 The mod-
elled HIV epidemic among PWID was initiated in
199943 with an initial cohort of PWID with 15% HIV
prevalence based on HIV prevalence estimates from
that time.44–46 The duration of injecting was assumed
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to be 6 years, consistent with recent data on the dur-
ation of current injecting (4 years).
The model assumes a low coverage and efﬁcacy of ART
at 58%47 based on recent data from Nairobi showing low
coverage among PWID (8% of HIV-infected PWID were
on ART in 2012) and low levels of viral suppression for
those on ART (4%) (A Kurth, Personal communication).
The baseline model assumes no coverage of OST, which
is the national situation at the time of writing. The model
was then used to consider the impact of OST scaling up
over 2015 to 10%, 20% or 40% of the PWID population,
with OST assumed to reduce the risk of injecting-related
HIV transmission by 50% as found in a recent systematic
review.11 We estimate the impact of this scale-up in OST
on reducing HIV prevalence and incidence over 5, 10
and 20 years. The projections assume that low-risk and
high-risk PWID are equally likely to go on OST, and to be
conservative they do not assume that PWID on OST have
better ARToutcomes as suggested by other studies.16–21
Lastly, a sensitivity analysis was undertaken to consider
the effect of changes in speciﬁc model parameters on
the 10-year impact of scaling up to 40% coverage of
OST. The sensitivity analysis considered lower efﬁcacies
of OST (lower conﬁdence bound from the systematic
review of 33%11), longer and shorter durations of inject-
ing (4 and 8 years), higher and reduced levels of sexual
HIV transmission (calibrated to a 0%, 4% or 12% HIV
prevalence among new initiates to injecting in 2012), dif-
ferent levels of heterogeneity (none or 6 factor differ-
ence in risk instead of 3), less like-with-like mixing (0%
or 25% instead of 50%) and ﬁtting to the lower and
upper bounds of the HIV prevalence in 2014 (16% or
23%, A Kurth, Personal communication). For all sensitiv-
ity analyses, except when the efﬁcacy of OST was
changed, the model was reﬁt to available HIV epidemio-
logical data, although some scenarios assumed a higher
HIV prevalence due to sexual HIV transmission or
among PWID overall.
Qualitative data
We also draw on in-depth interview data generated
through qualitative longitudinal research with 109 PWID
in Nairobi (n=30), Malindi on the North Coast (n=50)
and Ukunda on the South Coast (n=29).4 Around a
quarter (24) of these were followed up at least once.
Recruitment was facilitated through introductions from
community outreach projects, as well as via social
network chain referral. Undertaken in the 2 years prior
to methadone’s implementation, interviews focused on
the lived experience of HIV risk and its prevention, drug
treatment and addiction recovery efforts and on percep-
tions of the promise of methadone. Participants had a
mean age of 31 years (19–49), were predominately male
(70%; 76), and all but two had injected in the past
4 weeks, with almost all (97%; 106) injecting daily.
There was a mean of 7 years of injecting, with roughly a
quarter (29%; 32) reporting previous experience of resi-
dential rehabilitation. A similar proportion (28%; 31)
reported themselves to be HIV positive, with this being
highest in Nairobi (53%; 16).
Figure 1 Model schematic. The main model population subgroups are shown as blue squares. The blue lines denote
transitions between people who inject drugs (PWID) HIV associated infection states, black lines show which groups can infect
the susceptible PWID, and light grey arrows denote PWID leaving the model due to cessation of injecting (solid grey arrows) and
HIV morbidity (dashed grey arrows). The dark dashed box denotes that the non-PWID can infect either low-risk or high-risk
susceptible PWID. The inflows into the system are not shown but can either enter the susceptible or latent infected class
depending on the prevalence of HIV among newly initiating PWID.
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In addition, 43 brief interviews were undertaken with
key stakeholders in the ﬁelds of HIV prevention and
drug treatment. Key stakeholders included representa-
tives of: national policy organisations; international
development organisations; drug treatment providers;
HIV prevention professionals; law enforcement; and
community outreach projects.
Coding of qualitative data was simultaneous with data
generation, enabling the research to proceed inductively
over time and across sites. Following the verbatim
transcription of interviews, and translation from Swahili
to English where required, we ‘open coded’ for emer-
ging content before identifying core thematic categories
for subsequent coding,48 assisted by NVIVO, V.10.
Preliminary ﬁndings were fed back and ‘member
checked’ with participating community service organisa-
tions. We concentrate our analysis here on accounts
linked to drug treatment and methadone. All interview
extracts reported below (see boxes 1–7) are among
PWID unless otherwise marked as ‘stakeholders’.
Interview participants received 200 KSh (US$∼2.2) as
reimbursement and a food parcel.
FINDINGS
We chart the promise of methadone ﬁrst, using projec-
tions generated through mathematical modelling of the
potential impact on HIV transmissions, and second,
using qualitative data to explore perceptions of expect-
ation linked to methadone’s implementation.
The projected HIV effects of methadone
Our modelling attempted to account for sexually trans-
mitted HIV among PWID by allowing a proportion of
PWID to be already HIV infected at their initiation to
injecting (8%), and by assuming a continued rate of
sexual HIV transmission among PWID. The level of
injecting HIV transmission was then quantiﬁed by deter-
mining what additional HIV transmission is needed to
ﬁt the model to the observed HIV prevalence (20%)
among PWID as found in surveys undertaken by the
coauthors in 2014 (A Kurth, Personal communication).
The model ﬁt is shown in online supplementary ﬁgure
S2, with the modelling scenario suggesting an HIV inci-
dence of 3.8 per 100 person years among PWID in
Nairobi with sexual HIV transmission contributing a size-
able but minority proportion (40%) of these incident
HIV infections in 2014. However, up to 59% of the
prevalent infections are due to sexual HIV transmission,
because of substantial HIV transmission occurring
before they started injecting, with the HIV prevalence
among PWIDs possibly decreasing to only 12% in 2014
if no injecting HIV transmission had occurred in this
population.
The modelled impact of OST on HIV transmission in
ﬁgure 1 shows that the current anticipated scale-up of
OST over the next year (to 10% coverage) will only
result in a small relative reduction in HIV incidence of
about 5%, and HIV prevalence of about 2% over 5 years.
The impact generally increases slowly over the subse-
quent 15 years. If the coverage of OST is scaled up to
20% or 40% in Nairobi, then larger decreases in HIV
incidence and prevalence could occur, with a 10% or
19% reduction in HIV incidence occurring following
20% or 40% coverage of OST after 10 years, and about
half that decrease being achieved on HIV prevalence,
Box 2 The poverty of drug treatment opportunity
Limited access to drug treatment
I have not been taken to any rehab because rehab is money. If it
was free I would have gone…Just our own survival is a problem,
getting the stuff is a problem. You cannot be capable of paying
yourself for rehab, unless you get sponsorship. [extract 1]
Investing hope in sponsorship
I am praying I get a good sponsor, someone who will have mercy
on me then take me to rehab so that I stop taking drugs. [extract 2]
Recovery doubts
It [rehab] is like a garage. They are just going there to, you know,
clean out the spare parts. Then they come out, and it’s the same.
[extract 3]
To most people they think like rehab is the only way out, though
after rehab, people go into relapse once again. But they still
believe I did this mistake, I need to go back to start all over again,
as this is the only way out of this whole mess. [stakeholder,
extract 4]
Self-care and preserving hope
I am tired of being a drug user. I want to change my life. It is, I,
myself, who gives hope to myself. I have started to reduce [my
dose] not because somebody has told me to stop, no, I decided
for myself. [extract 5]
Urgency for recovery
I want to go to rehab and to quit drugs. If I quit drugs my life will
become good. If I don’t quit, my friend, if you come back in a
year, you will hear that I am dead [from his HIV]. I am telling you
the truth. If I don’t quit, I will die. [extract 6]
Box 1 The narrative of addiction recovery desire
Recovery desire
I am wasting my time, you know. I want to live like before. I want
to go back to my life before. [extract 1]
Return to normalcy
I am trying my best so that I can return to normal. That is why I
am stopping shooting. [extract 2]
If I can stop taking drugs, and cease using the injection, then I
can lead a good life, I can then live a good life without the inject-
ing, and I will look at life positively. [extract 3]
Reintegration into social life
I will reform. I will be back, and again I will be important in the
community…I want to go back. I want to go back to my job, and
to start my family again. [extract 4]
It is for me to show them I am their parent, to give them what
they want, take them to school, to take care of them like other
people take care of their kids. [extract 5]
Generalised hope for recovery
I don’t give up, I will give up when I die…In my heart I say ‘one
day I will quit the habit and come back’. [extract 6]
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although the impact on HIV prevalence increases over
time (ﬁgure 2).
The results of the sensitivity analysis (see online sup-
plementary ﬁgure S3) suggest that in general our model
projections are conservative, although the estimated
impact is reduced if: (1) OST has a lower efﬁcacy for
reducing HIV transmission in this setting; (2) PWID
inject for longer than we currently assumed; (3) There
is more sexual HIV transmission than is currently
assumed; or (4) the HIV prevalence among PWID is
lower than is currently estimated in recent surveys. In
particular, the assumed level of sexual HIV transmission
has a considerable effect on the model’s impact projec-
tions. Lastly, the level of injecting risk heterogeneity and
like-with-like mixing had little effect on the impact
projections.
Kenya’s poverty of drug treatment opportunity
The social relations of expectation regarding metha-
done’s introduction is framed by a context of ‘poverty of
drug treatment opportunity’.4 Qualitative interview
accounts of PWID emphasise the salience of narratives
Box 3 Methadone as a narrative of aspiration
Communicating cautious optimism
I don’t know what people expect from it, but for us, I know it
might be a bit disappointing. We anticipate local dissent, so we
want to be cautious. [stakeholder, extract 1]
Communicating recovery hope
We have done a lot of awareness raising, just telling them [drug
users] it is the only hope that we have. So we are selling it out to
them like every time I meet them I tell them, that there is hope
methadone is coming. [stakeholder, extract 2]
Communicating social inclusion
They [drug users] are excited. But you see, for this community,
the target population [drug users], anything that comes for free is
exciting to them…Also, the realisation that somebody now is
looking their way, that somebody now us giving them attention in
the form of methadone, and so they are excited, they say the
Government is now thinking about us. [stakeholder, extract 3]
Communicating HIV prevention hope
The reality of zero infection may not simply be a myth or a
dream, it can become a reality…If you put 80% of people who
inject drugs on either methadone or NSP you are reducing signifi-
cantly new infections of HIV. [stakeholder, extract 4]
We also need methadone for adherence, adherence especially to
HIV drugs and for appointments like for TB…The only way we
can stabilize them [PWID] is through methadone so if we have
strong methadone programmes we will have effective HIV pro-
grammes, but in our programmes now the levels of adherence
are very low. [stakeholder, extract 5]
Box 4 Methadone as a solution to recovery
Hope for recovery
They are saying that if someone takes it, he will stop smoking
stuff or injecting…If I take it, I will stop using drugs. If I cannot
take it, then I’ll continue injecting. [extract 1]
Recovery through withdrawal management
I have heard that if you take it, you will not have pain. There is no
way that you will have desire for the drugs, so now if you take
this thing you will be OK. [extract 2]
Recovery made easier
If you want to stop stuff, it will not be hard, as you will not suffer
when you decide to stop. [extract 3]
If I don’t feel withdrawals, isn’t that an easy way of staying away
from addiction? [extract 4]
Recovery of citizenship
Many people don’t want to go to rehab. It is like time wasting. It’s
like you waste your time. Six months you are locked somewhere
and after that you come out you don’t have the skills, you cannot
be employed, you are just idle. That will take you back to using
drugs. But with methadone, if you are working you don’t have to
go to the rehab, you can control, you can substitute the heroin
with the methadone. [extract 5]
Box 5 Methadone as a hope for community
Hope for community recovery
The idea is as soon as people start using this new medicine from
outside, these people are going to be OK…They perceive that
people will stay away from drugs, and there won’t be people
using drugs. So there won’t be any problems related to drug use.
[…] We give methadone to the people and the problem is over.
They come, they take the dose, and they don’t need to take
drugs, they don’t need to inject themselves, they don’t need to
steal, they can go to work, yeah, that’s what we want. [stake-
holder, extract 1]
Hope for crime reduction
An advantage is as far as people take their methadone dose, then
they don’t need to steal, they don’t need to rob anybody, and they
don’t need to get into prison. [stakeholder, extract 2]
Community acceptance
Most people said no, no, no! We don’t need needles here, don’t
bring needles here. But what’s this other one? Methadone. What
is it? This is the kind of medicine they [drug users] will need,
yes, bring it, bring it, that’s what we want! [stakeholder, extract 3]
Most of the people were asking instead of bringing the needles
and the syringes, why don’t they bring the methadone, so I think
that will be much better. [stakeholder, extract 4]
A better solution
It was easier to convince about methadone because as we were
engaging with the communities they could tell us that rehabilita-
tion itself hasn’t worked, hasn’t had a high success rate, so it is
really something that the communities were open to, and willing
to implement. [stakeholder, extract 5]
The cultural salience for a ‘quick fix’ narrative
We are so much built into the mentality of wanting short-cuts. In
Africa, most of us think like we should look for a short-cut. That’s
why we have issues like the bush doctors, magicians, witch
doctors, they are trying to give you a quick fix…That mentality
also applies to medicine that’s mysterious like methadone. [stake-
holder, extract 6]
The problem with the community is that they think this is just like
magic…They expect that somebody will change abruptly, that
somebody will become very good, they will be decent, they won’t
steal…They just expect a normal human being coming out from
drugs and changing immediately. [stakeholder, extract 7]
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of desire for addiction recovery despite major constraints
on drug treatment access. Despite the primary focus of
our qualitative research being HIV risk and its preven-
tion, a striking feature of interview accounts is the strong
emphasis they give to voicing desire for self-recovery
(box 1). Here, the overcoming of heroin addiction is
expressed as a ‘return to normalcy’, symbolised by
reintegration into work, family and social life (box 1,
extracts 4–5).
As noted above, the primary form of drug treatment
available is private residential rehabilitation, offering
detoxiﬁcation with counselling, usually over 3–6 months,
at a monthly cost averaging around 10 000 KSh (US
$∼114). Such treatment is prohibitively expensive for
most (box 2, extract 1). In response, people invest their
hope of recovery on the slim chances of securing spon-
sorship from local benefactors and, failing these, on
their self-recovery efforts (box 2, extract 2). This is even
despite the presence of strong treatment doubts given
the norm of relapse following rehab, and rehab most
commonly being used in practice as a ‘garage of repair’
rather than as a means of sustained ‘recovery’ (box 2,
extract 3). We ﬁnd that circulating narratives of recovery
aspiration invest narrowly in the rehab approach, yet its
lived experience is alternatively described as a form of
‘respite’ and ‘harm reduction’ from day-to-day drug use
and surrounding risk environment, with any recovery
effects short-lived and easily undone (box 2, extract 4).
Nonetheless, hopes of addiction recovery desire may
persist despite such poverty of recovery opportunity
(box 1, extract 6; box 2, extract 5). We also ﬁnd that an
intensifying sense of time running out, especially in the
light of the urgency of HIV complications or transmis-
sion risks, acts a spur to maintaining recovery desire and
to pursuing alternative recovery strategies, largely
through self-treatment, when rehab opportunities fail to
materialise (box 2, extract 6).
Methadone hope and expectation
Methadone therefore enters an addiction treatment
context characterised by a cultural script of recovery
desire coexisting with rationed expectations of recovery
opportunity. In this context, methadone holds much
promise. With around 1500 treatment slots initially
planned across four sites, methadone’s implementation
is ‘cautiously’ managed (box 3, extract 1). However, with
rapid scale-up envisaged, stakeholder accounts highlight
methadone’s implementation as a project of aspiration
in relation to hopes of addiction recovery (box 3,
extracts 2–4) as well as HIV prevention and care (box 3,
extracts 5–6).
Hope for recovery
A core feature of interview narratives of methadone
promise is that such treatment is posited as a solution to
the problem of addiction recovery. Given the norm of
relapse linked with rehab, methadone engenders hope as
a better recovery alternative (box 4, extracts 1). Rehab is
presented as failing to prevent relapse through its incap-
acity to stave off withdrawals, whereas methadone pro-
mises sustained recovery through its management of
opiate withdrawals (box 4, extract 2). An emerging narra-
tive envisions recovery made ‘easier’ by methadone
(box 4, extract 3–4). Moreover, with addiction recovery
envisaged as a return to normalcy and social inclusion
realised through reintegration into work, family and
social life (box 1), methadone is positioned as a technol-
ogy of hope for enabling ‘recovery of citizenship’ where
rehab has failed on delivering such promise (box 4,
extract 5).
Hope for community
Methadone as a hope for recovery is not only a feature
of the personal accounts of drug users, but is incorpo-
rated into broader narratives of community hope and
acceptance. Community members envisage methadone
as a solution to local problems of addiction (box 5,
extract 1). A key attraction here is the promise of crime
Box 6 Moderating hope and rationing expectation
Experiencing unrealised promise
They (community project) promised me (a place in rehab), they
promised me. Even I am tired now. I’m still waiting. [extract 1]
She kind of promised me that if I kept on coming to the (counsel-
ling) sessions, there would be a possibility that the man in
charge, if he listened to my case, will think it worth it, I could get
to go to rehab…I went there every day, but I never got the
chance. [extract 2]
Implementation constitutes waiting
We are waiting for that medicine to reduce using. We have been
waiting for it for a while, but we have not yet got it. [extract 3]
We still don’t know. We are waiting to hear from them [Ministry
of Health] about the whole issue, the whole plan [interview 1].
We still haven’t heard when the methadone is going to start in
Kenya [follow-up interview]. [stakeholder, extract 4]
Rationed expectations
Practically, we haven’t heard anything about it on the ground
again. We are waiting for this to be a reality…They are very disap-
pointed because it is not coming as fast as it could be. [stake-
holder, extract 5]
We don’t even talk about methadone anymore. Every time we ask
[community projects] we are told maybe next month…And now
for two years they have been telling us that it is “soon”. It has
come to a point where we don’t believe there is going to be any
methadone programme…We were supposed to start last year in
February, and now it’s been two years…People were eager at
first. They thought this is our chance to get out of this shit, but
because nothing has happened, people no longer think about it.
When you talk about it, they think ‘Ah, you are wasting your time
telling us about methadone’, because we don’t believe it will
happen. [extract 6]
Methadone uncertainty
I haven’t seen it yet, but I’ve heard something like that, which is a
substitute of heroin, but I haven’t seen if it works. [extract 7]
I heard something like that methadone is drunk, that they have
got that drug to try and assist people who are using drugs to
stop those drugs using that medicine. [extract 8]
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reduction (box 5, extract 2). Talk of the promise of
recovery potential ratchets upward expectation, and
community responses to the proposal to implement
methadone, which stand in sharp contrast to those of
syringe exchange, are generally framed by eager accept-
ance (box 5, extract 3–4). This is especially the case
given the circulating narratives of disappointment
regarding rehab’s recovery potential (box 5, extract 5),
and a cultural tendency—according to some—for ‘quick
ﬁxes’ to community problems (box 5, extracts 6–7).
Rationed expectation
A key contextual factor shaping the production of
methadone hope locally is a norm of rationed expect-
ation surrounding access to drug treatment (box 2).
With only slim chances of access to rehab largely gener-
ated through philanthropic sponsorship (box 2, extract
2), and with communication between users and commu-
nity projects concerning access to rehab characterised by
ambiguity, a culture of ‘rationed expectation’ rather
than ‘concrete hope’ or ‘entitlement’ to treatment pre-
vails.4 This means that methadone offers renewed hope
but in a cultural context of ‘hope moderation’, managed
through the rationing of expectations borne out of the
experience and disappointment of previous unrealised
treatment promises (box 6, extract 1–2). Accounts
emphasise that methadone’s implementation has been
characterised by 2 years of waiting, in the absence of cer-
tainty and in the presence of repeated revisions to pro-
mised delivery dates and organisational arrangements
(box 6, extracts 3–4). The ambiguity surrounding metha-
done’s implementation reproduces a sense of fragile
expectation (box 6, extract 5). For some, methadone is
already depicted as a symbol of ‘dashed hope’, repre-
senting a familiar tension between narratives of aspir-
ation and talk of recovery desire on the one hand, and
experience of unrealised promise, disappointment and
limited recovery opportunity on the other (box 6,
extract 6). With methadone’s ‘implementation’ constitut-
ing an uncertain waiting, there is the risk of help-seeking
disengagement among would-be patients (box 6,
extract 6). Many others have yet to invest hope in the
promise of methadone for they remain uncertain of its
impact potential (box 6, extracts 7–8).
Box 7 Methadone’s implementation social science
Maintenance
The questions were asked (by community members) ‘What’s the end game of all this?’, ‘Are they going to be on methadone for life?’, ‘Are
they going to be tapered off?’. [stakeholder, extract 1]
It [methadone] will feel like if you want to get into drugs you can get into drugs, no restrictions, no boundaries, nothing, just go and take
your dose and off you go. So I’m still using drugs because this is a substitution, because I’m still gonna be feeling OK, feeling good,
without stealing from anybody. [stakeholder, extract 2]
Eligibility and threshold
We are starting cautiously and we’re trying high threshold, but we feel that is the right direction… We are trying to get people who we are
sure can be on followed-up, you know, like may be because they’ve been on NSP, they’ve been adherent… We’re really trying to avoid guys
with a lot of poly drug use. [stakeholder, extract 3]
We are promoting the philosophy of high volume, low threshold, getting the maximum in treatment. [stakeholder, extract 4]
Demand
We know it’s been a long time since we started to talk about methadone so we know a lot of guys are waiting for it. We might anticipate a
high demand for the methadone programme…So we anticipate that we might not be able to respond fully initially to all of the demands.
[extract 5]
We cannot afford to take somebody to a rehab, so you can see as soon as methadone comes these guys are going to run on the methadone
bandwagon. The issue is, is the Government ready to fund all the drug addicts with methadone, and they are not. [stakeholder, extract 6]
People will think we don’t need the rehab no more, because they will know like there is something else better than the rehab. Most people
will go for the OST because it will be free. [extract 7]
Diversion, corruption and security
[So you think demand will outweigh supply?] Of course, and that is why now we are going to have black methadone, that is why automatic-
ally black market methadone will come, because every parent will be wanting to have methadone, and the drug barons will say OK, we can
supply you the methadone…The system will be the same. It will be the same forest, just different monkeys…That’s what will happen as the
Government can’t afford to buy methadone for everybody. […] There are people who will also want to go and steal the methadone…There
are also people who are going to design ways to sell black market methadone, so we might have corrupt technicians or hospital guys that
will go and sell the methadone to the black market. [stakeholder, extract 8]
Methadone as story to be made
This thing [methadone’s implementation] is all going to depend on the new beliefs that drug users are going to build around methadone after
they have seen it, tested it…You see, we don’t know what stories are going to be made out of how the pilots start. [stakeholder, extract 9]
Implementation as a ‘managed secret’
It’s not something that we can launch. It’s not something that we can show case publicly…The silence [of religious and community leaders]
was key, because it was much better than opposition. [stakeholder, extract 10]
We decided to do it [implement NSP] very cautiously, secretly, so that we don’t raise anybody’s attention, to the extent that we blow the
whole thing before it is even launched, so just to be on the safe side…Secretly, because after all what we are aiming for it not to make
everybody know like this is what we are doing. [stakeholder, extract 11]
8 Rhodes T, et al. BMJ Open 2015;5:e007198. doi:10.1136/bmjopen-2014-007198
Open Access
Implementation social science
Qualitative accounts of health professionals emphasise
additional factors critical to determining the process of
methadone’s implementation and to managing its com-
munication of ‘promise’ (box 7). Qualifying methadone’s
delivery as a route to ‘recovery’, as ‘maintenance’ or as
‘harm reduction’ is fundamental, especially in the light
of community recovery expectations (box 5) and con-
cerns that methadone may simply act to ‘substitute’ one
drug for another (box 7, extracts 1–2). The ‘cautious’
introduction of methadone (box 3, extract 1) implies for
some national policy stakeholders a ‘high threshold’
approach to eligibility, concentrating on those presumed
to offer the best chances of adherence, with an emphasis
on demonstrating avoidance of illicit use, commitment
towards abstinence and a risk of withdrawal from the pro-
gramme if random urine tests show evidence of illicit
drug use (box 7, extract 3). Others hope for lower thresh-
old access (box 7, extract 4). Managing demand is an
immediate concern given the high hopes, the long
waiting and the ﬁrst real opportunity for users in
Kenya to access drug treatment without a fee (box 7,
extracts 5–7). Diversion, corruption and security are also
concerns (box 7, extracts 8). Initially, methadone’s imple-
mentation is constituted by stakeholders as a problem of
management primarily in relation to its representation, so
as to moderate community expectation and acceptance.
What is said about methadone determines what it ‘is’,
and thus how it is negotiated into perceived acceptance,
especially in the period immediately prior to its introduc-
tion (box 7, extract 9). Alongside its cautious introduc-
tion as an intervention unchallenging of circulating
hopes of recovery, implementing methadone as a
‘managed secret’ to avoid generating community resist-
ance is one adopted strategy (box 7, extract 10), as used
when implementing syringe exchange a year earlier
(box 7, extract 11).
DISCUSSION
Using a mix of mathematical modelling and qualitative
interview data, we have projected the potential impacts
on HIV transmission as well as outlined the dynamics of
community expectation in relation to the promise of
implementing methadone in Kenya. We recognise that
these are preliminary observations. Our aim has been to
demonstrate the value of mixed-method approaches to
evidencing methadone’s implementation in new settings
and to begin charting the effects of such intervention
promise.
What is the potential HIV prevention impact of
methadone in Kenya?
Our analyses are the ﬁrst to present a dynamic HIV trans-
mission model to assess the potential impact of OST in
HIV epidemics in an African setting with high levels of
sexual HIV transmission. Despite the possibility of sub-
stantial sexual HIV transmission, our modelling suggests
that methadone could be an important component of
any intervention package aiming to reduce HIV transmis-
sion among PWID in Kenya. The high coverage levels of
OST (40%) could rapidly reduce HIV incidence by 20%
over 5 years, which would then slowly reduce HIV preva-
lence by 10% or more over 20 years. Although these dem-
onstrable impacts are epidemiologically important, they
also emphasise that OSTon its own will be insufﬁcient for
controlling HIV within this population, with combined
interventions including NSP, ART as well as ongoing
sexual risk reduction most likely being needed.
We acknowledge uncertainty in how our model
assesses sexual HIV transmission potential and our sensi-
tivity analysis emphasises that this will result in uncer-
tainty in our impact projections of OST. Future models
assessing the impact of scaling up combination HIV pre-
vention among PWID need to develop more reliable
indicators of sexual HIV transmission among PWID.
This could be achieved by getting better estimates of the
HIV prevalence and incidence among PWID prior to ini-
tiating injecting, possibly through following young non-
injecting drug users, and then comparing whether their
sexual risk behaviours change following initiating inject-
ing or not. Alternatively, modelling could be used to
assess the utility of other markers of sexual and injecting
HIV transmission risk, such as HCV and HSV-2.49 50
Initial insights using HCV prevalence data from Nairobi
and previous modelling suggest a similar proportion of
HIV infections due to sexual HIV transmission as our
modelling estimated here.50 Phylogenetic data from
PWIDs and the general population could also be useful
for understanding how HIV transmission between the
groups is linked. It is also important that the nature of
sexual HIV transmission is included with greater realism
in future models, incorporating gender heterogeneities
in the degree to which they drive sexual HIV transmis-
sion (A Kurth, Personal communication), as emphasised
in a recent PWID study from Tanzania,51 and differences
in the degree to which they are recruited onto OST.52
Figure 2 Projected impact of opioid substitution treatment
(OST) on HIV prevalence and incidence at varied coverage levels.
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Model adjustments might also be required in the light
of local patterns of injecting drug use and how these
potentially link to risk practices, such as sexual risk in
the light of amphetamine injection.53 Lastly, while our
estimate for the efﬁcacy of OST emanates from a recent
systematic review,11 it is important to emphasise that
there are as yet no data documenting the HIV preven-
tion efﬁcacy of OST in African settings. It is possible that
OST could have lower efﬁcacy in such settings due to
the extent of sexual HIV transmissions occurring, or
because of context-speciﬁc factors. However, it is also
possible that OST may have a greater impact than we
projected because of improvements in the uptake and
outcomes of ART among PWID on OST.16–21
What is the making of methadone in Kenya?
Our qualitative analyses emphasise how intervention
expectation is a product of its social context. We ﬁnd
that a social condition characterised by a ‘poverty of
drug treatment opportunity’ and a culture of ‘rationed
expectation’ in relation to access to care frame perspec-
tives of hope and expectation related to the promise of
methadone. The combination of the salience of the
addiction recovery narrative and the norm of the limited
recovery effect linked to current drug treatment options
heightens hope for recovery through methadone. The
strong desire for recovery is envisaged as a return to nor-
malcy, symbolised by a renewal of citizenship and social
inclusion, which rehab has largely failed to deliver,
despite its narrative of recovery promise. Methadone
offers an alternative technology of recovery hope, not
only for individuals but also for community, and hence
the apparent social acceptability of methadone’s pro-
posed implementation.
While some ‘post-AIDS’ drug policies of the West are
drifting towards a narrative of addiction recovery in an
effort to de-emphasise methadone as an intervention of
‘harm reduction’,35 36 drug policies in Kenya are begin-
ning to incorporate harm reduction in relation to HIV
prevention alongside predominating addiction recovery
narratives.5 Kenyan national policy, in keeping with the
thrust of global evidence, envisages methadone primar-
ily in relation to HIV prevention, yet affected communities
—including people who inject drugs—appear to frame
methadone primarily in relation to addiction recovery.
While partly borne out of an effort to ‘protect’ new
methadone interventions from community resistance,
the cautious handling of its implementation may empha-
sise ‘high threshold’ eligibility and demonstrated com-
mitment towards abstinence, reproducing methadone as
a symbol of recovery hope rather than pragmatic harm
reduction. Evaluation of the health impacts of OST
question it as a primary role in addiction recovery, with
under 5% of those in OST annually achieving abstin-
ence,54 55 and with recovery odds reducing as the dur-
ation of OST increases.56 The social construction of
methadone in the present as a hope for addiction recov-
ery is in danger of producing ‘dashed hopes’ of the
future, especially if those falling short of recovery expect-
ation come to symbolise, as well as internalise, treatment
or self-failure.57 58
When communicated intervention aspirations are dis-
rupted or unfounded, treatment and health expecta-
tions may be rationed, as well as hopes dashed, in turn
feeding treatment doubt as well as disengagement, and
even resistance, in response to the sense of false promise
experienced.32 What might be the personal and commu-
nity effects if methadone’s implementation results in a
sense of false recovery promise, no matter its HIV pre-
vention potential? What might be the effects if demand
management results in a sense of inequity among those
who also believe themselves to be deserving of treatment
opportunity? In situations of insecure HIV or drug treat-
ment delivery, it is people in need of treatment and
their treatment providers who tend to navigate the psy-
chological effects of the fallout between high hopes and
rationed expectations.32 This cautions against the gener-
ation of a rhetoric of aspiration when promoting inter-
ventions in new settings as well as when projecting their
potential.
The emergent primary framing of methadone in rela-
tion to addiction recovery rather than HIV prevention in
this setting suggests a different mediation of methadone
to that promoted globally in HIV prevention oriented
policy.1 9 We see emerging evidence of a collision of fram-
ings in what constitutes ‘methadone’ between potential
users and affected community members on the one
hand, and providers, policymakers and international
policy advisors on the other. Of this, stakeholders are
aware (and their accounts emphasise methadone as a
‘communication problem’ to be managed), but it none-
theless emphasises that methadone is a negotiation, some-
thing in the making, rather than secured as a ‘universal
given’ by its ‘evidence-base’. This collision of framings in
relation to expectation of effects also speaks to the differ-
ent kinds of data generated in mixed-method implemen-
tation science, for instance, between the data we have
generated through modelling (oriented to HIV preven-
tion impact) and that which we have generated through
qualitative interviews (which have captured participant
perspectives on recovery). Modelling methadone’s poten-
tial as an HIV prevention solution tends to reproduce pre-
dominant policy framings, whereas qualitative analyses
may question these, proffering alternative framings
grounded in local practices. Both are needed as part of
the dialogue investigating the promise of methadone.
Developing implementation science
Prior to implementation, the ‘promise’ of new technolo-
gies shapes the present through what is said rather than
through what is carried out.30 31 Intervention promise
does not transcend social contexts universally but is vari-
ously made and deployed, in context, according to what it
is represented to ‘mean’ and how it is ‘used’ as a
resource in the negotiation of competing stakeholder
interests and values. It would be a considerable oversight
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not to develop a social science of methadone’s imple-
mentation in Kenya and the East Africa region.
Fundamental questions frame its delivery and deﬁnition,
including ambiguity concerning its role in addiction
recovery relative to harm reduction, how demand is to
be managed, as well as concerns in relation to diversion,
corruption, security, provider training and capacity,
medication adherence barriers and facilitators, and com-
munity support versus resistance. There is a surprising
absence of implementation social science exploring the
social relations of methadone interventions, especially in
lower income settings, despite a robust evidence-base in
relation to health effectiveness. The extreme case of
Russia and its vociferous resistance to OST despite
strong evidence-based counter advocacy in the face of
uncontrolled HIV epidemics among PWID presents a
strong retrospective case for exploring the social science
of intervention expectation and engagement.14 In the
case of Kenya, the time is now, as expectations in rela-
tion to the promise of methadone are formed. As well as
determining the impact through evaluation and model-
ling, we highlight the need to capture how intervention
expectation is shaped over time through the reciprocal
relations between what is said (for instance, in relation
to recovery hope) and what is experienced (for instance,
in relation to recovery effect).
Understanding the promise of methadone requires an
appreciation of how this object of intervention is ‘made’
through its representations locally and, in this process,
how global ‘evidence’ about it is negotiated and used.
This form of implementation science is critical to prop-
erly describing how new interventions and their uptake
are ‘enabled’ or ‘disabled’ by their policy and social
environments. In turn, this helps build social interven-
tions as a means of moderating aspiration and fostering
‘realistic local expectation’. There is a neglected role for
ethnography and qualitative methods in implementation
science, which crucially does not presume the attributes
and effects of methadone to be ﬁxed, essential or free of
context, but rather consider these to be ‘something in
the making’. A social science of intervention expectation
broadens questions of implementation science from ‘how
can interventions of evidenced-based effect be best trans-
lated into new settings?’ to ‘how are new interventions
and expectations made and evidenced locally?’. Both
questions are needed, but the latter is rarely applied.
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